Latest stories

At least 56 migrants die in weekend shipwrecks off Senegal and Greece

At least 56 migrants die in weekend shipwrecks off Senegal and Greece

At least 34 people died when a boat capsized near Loumpoul in northwestern Senegal, while at least 22 died in two separate incidents south of Crete. IOM chief Amy Pope blamed smugglers and traffickers for charging people for journeys on boats "not fit for the sea."

Ribo Files EU Clinical Trial Application for Dual-Targeting siRNA SR122 in Dyslipidemia

Ribo Files EU Clinical Trial Application for Dual-Targeting siRNA SR122 in Dyslipidemia

Suzhou Ribo Life Science and subsidiary Ribocure Pharmaceuticals have submitted a Phase I clinical trial application in the EU for SR122, a dual GalNAc conjugated siRNA targeting ApoC3 and PCSK9 for dyslipidemia. The randomized, placebo-controlled study will assess safety, tolerability, pharmacokinetics and pharmacodynamics in healthy participants.

EICMA Opens Its Largest Edition Yet at Fiera Milano Rho

EICMA Opens Its Largest Edition Yet at Fiera Milano Rho

The 83rd EICMA International Two-Wheeler Exhibition opened at Fiera Milano Rho with 765 exhibitors, 2,142 brands from 52 countries and ten halls, its largest edition at the venue. The public attended from 5 to 8 November after two trade days.

Consello Adds Two Managing Directors to Dublin Office

Consello Adds Two Managing Directors to Dublin Office

Consello has appointed Niamh Garvey and Peter Davis as Managing Directors in its Dublin office, citing their expertise in strategic communications, public policy, transactions and capital markets. The firm said the hires strengthen its CEO advisory capabilities in Ireland.

Pierre Fabre and XtalPi Team Up on AI-Driven Drug Discovery

Pierre Fabre and XtalPi Team Up on AI-Driven Drug Discovery

Laboratoires Pierre Fabre and XtalPi have signed an agreement to collaborate on discovering novel clinical candidates in oncology, potentially dermatology, and rare diseases. XtalPi will apply its AI and robotics platform to design small molecule therapeutics against undisclosed targets.